Comparing different dosing schedules of Vismodegib for advanced skin cancer

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

This study is testing different ways to take Vismodegib to see which schedule works best for adults with advanced skin cancer.

Quick facts

• Phase: EARLY_PHASE1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute (other)
• Locations: 1 site (Tampa, Florida)
• Trial ID: NCT05651828 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the tolerability and effectiveness of four different dosing schedules of Vismodegib, a medication used for advanced basal cell carcinoma. Participants will be assigned to either personalized intermittent dosing schedules or fixed intermittent and continuous dosing regimens. The study will involve adult patients with confirmed locally advanced basal cell carcinoma, and it will assess how well these different approaches manage the condition. The goal is to identify the most effective and patient-friendly dosing strategy.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with confirmed locally advanced basal cell carcinoma who can provide informed consent.

Not a fit: Patients with early-stage basal cell carcinoma or those who are not able to tolerate the medication may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more effective and personalized treatment options for patients with advanced basal cell carcinoma.

How similar studies have performed: Other studies have shown promise in using personalized dosing strategies for cancer treatments, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Patients with a cytologically or histologically confirmed locally advanced basal cell carcinoma. (Nodal involvement permitted)
* Adult males or females 18 years of age or older at time of signing informed consent. All races and ethnicities are eligible, and no upper limit of age is specified.
* Must have ability to comprehend and the willingness to sign written informed consent for study participation.
* Patients must have at least one cutaneous tumor site amenable to direct and accurate measurement by ruler/calipers.
* Patients may have received prior hedgehog inhibitor therapy (if more than 6 months prior) or other systemic treatments for basal cell carcinoma in the past.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2
* Agreement not to donate blood or blood products during the study and for 24 months after discontinuation of vismodegib.
* Patients must have adequate hepatic, renal, and bone marrow function as defined in the protocol.
* Participants must have a negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year.
* Women of reproductive potential are required to use two forms of acceptable contraception (including one acceptable barrier method with spermicide) during therapy and for 24 months after completing therapy.
* Female patients must agree not to become pregnant or donate lactation during treatment and until 24 months after stop of treatment. Male patients must use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 3 months after the last dose to avoid exposing a pregnant partner and unborn fetus to vismodegib. Male patients must agree not to donate sperm during the study and for 3 months after discontinuation of vismodegib.

Exclusion Criteria:

* Received prior hedgehog inhibitor therapy in the last 6 months
* Female patients who are pregnant, intend to become pregnant or are nursing.
* Uncontrolled intercurrent illness including, but not limited to, serious infection. Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.
* Previous malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessment.
* Inability or unwillingness to swallow capsules.
* Any known allergy, hypersensitivity or severe reaction to vismodegib or any of the ingredients
* Co-treatment with a statin or St. John's Wort.

Where this trial is running

Tampa, Florida

• Moffitt Cancer Center — Tampa, Florida, United States (RECRUITING)

Study contacts

• Principal investigator: Zeynep Eroglu, MD — Moffitt Cancer Center
• Study coordinator: Sy Olson-Mcpeek

Conditions: Advanced Basal Cell Carcinoma, Skin cancer